The tests of Lipozyt Marker are currently not available on the market. The market launch is planned for winter 2021.

Benefits of the personalized therapy
The main goal of treating type-2-diabetes is to delay the medical burden for as long as possible to maximize the patient's quality of life.
Personalized therapies are the key to success in postponing or even eliminating the use of insulin and the onset of comorbidities with type-2-diabetes. Personalized therapies go beyond purely symptomatic treatment and aim at personalised therapy.
The Lipozyt Marker tests provide a high-quality toolset that enables physicians to plan and control personalized therapies for their type-2-diabetes patients.

Recommendations for the therapy choice
Finding a suitable treatment for an individual patient’s type-2-diabetes is getting ever more complex. The choice of acute symptomatic therapy (e.g., metformin, insulin) is relatively straightforward. However, choosing a systematically personalized therapy places significant demands.
The complexity of the relevant national guidelines, the large number of existing drugs (and drug combinations) and finally the introduction of further innovative therapy options represent high and time-consuming hurdles for the selection of a patient-optimal therapy approach.
With DiaSquare's results, doctors receive immediate, patient-specific recommendations that help with planning a personalized therapy for an individual the patient.

Assistance with therapy control
The systematic control of a systematic causal oral antidiabetics therapy of type-2-diabetes is an essential prerequisite for the long-term therapeutic success. In addition to the symptomatic control, the control of changes in the dynamics of the metabolism of the diabetic patient is of extreme importance.
With our DiaCon test, the attending physician gains a reliable and efficient test for systematic therapy control. If necessary, the test results will include recommendations for therapy adjustment.

Decision-making with bariatric surgery
Bariatric surgery is an innovative form of therapy that, in some cases, provides good results in treating type 2 diabetes.
However, not all patients benefit equally from bariatric surgery for their type-2-diabetes. This uncertainty presents the treating physician and the patient with a decision-making problem in which to weigh the potential benefit with the certain side-effects and health-implications of this intervention.
With DiaBar we determine the patient-individual probability of success for bariatric surgery in type-2-diabetes and thus offer a decision-making aid for this form of therapy.

High quality patient care
With our patented machine-learning based mRNA assays in combination with a blood-draw, we offer the treating physicians a high-quality instrument that can significantly improve the service he provides in patient-care for diabetics.
Immediate access to patient-individual recommendations cuts-short the time until the start of patient-optimized therapy. At the same time, the patient gains the assurance of receiving an effective and personalized treatment.

Use in early detection and prevention as part of check-ups
Prevention and regular check-ups play an increasingly important role in early-diagnosis and prevention of type-2-diabetes.
The tests of the Lipozyt Marker, and especially the DiaPro, are tailored to these requirements. They enable for early detection of diabetic dynamics and developing insulin resistance years before existing tests show any results. In addition, they are suitable for the identification of undiagnosed diabetics, i.e. those patients who can not be identified with presently available tests.

Test procedure
For all our tests, a sample is taken by fine needle aspiration of the subcutaneous abdominal fat tissue and is further processed by laboratory techniques. The results are evaluated within the framework of SOMs and the patient is thus classified in a specific, therapy-relevant subgroup.
The tests are all designed to allow the attending physician a classification of the patient into specific groups. To these groups risk profiles are assigned with regard to the respective diagnostic problem. In addition, the individual measurements allow statements as to whether and through which individual customized medication the patient can be supported.

You need more information ?

We are happy to answer your questions.